[go: up one dir, main page]

ES2363975B8 - Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide. - Google Patents

Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide. Download PDF

Info

Publication number
ES2363975B8
ES2363975B8 ES201030162A ES201030162A ES2363975B8 ES 2363975 B8 ES2363975 B8 ES 2363975B8 ES 201030162 A ES201030162 A ES 201030162A ES 201030162 A ES201030162 A ES 201030162A ES 2363975 B8 ES2363975 B8 ES 2363975B8
Authority
ES
Spain
Prior art keywords
amiloid
tau
prevention
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201030162A
Other languages
English (en)
Other versions
ES2363975A1 (es
ES2363975B2 (es
Inventor
Luis Miguel Botana López
Eva Alonso López
Carmen Vale Gonzalez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to ES201030162A priority Critical patent/ES2363975B8/es
Priority to EP11739430.4A priority patent/EP2535335A4/en
Priority to PCT/ES2011/070078 priority patent/WO2011095668A1/es
Priority to US13/577,537 priority patent/US20130035302A1/en
Publication of ES2363975A1 publication Critical patent/ES2363975A1/es
Application granted granted Critical
Publication of ES2363975B2 publication Critical patent/ES2363975B2/es
Publication of ES2363975B8 publication Critical patent/ES2363975B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la yesotoxina, análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y {be}-amiloide.#La presente invención se encuentra dentro del campo de la biomedicina y de la química farmaceútica. Específicamente, se refiere al uso la yesotoxina, sus derivados y análogos para la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades neurodegenerativas relacionados con niveles anormales de proteínas tau y {be}-amiloide, como por ejemplo la enfermedad de Alzheimer.
ES201030162A 2010-02-08 2010-02-08 Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide. Active ES2363975B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201030162A ES2363975B8 (es) 2010-02-08 2010-02-08 Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide.
EP11739430.4A EP2535335A4 (en) 2010-02-08 2011-02-07 USE OF YESSOTOXIN AND ANALOGUE AND DERIVATIVES THEREOF FOR THE TREATMENT AND / OR PREVENTION OF NEURODEEGENERATIVE ILLNESSES RELATING TO TAU AND BETA AMYLOID
PCT/ES2011/070078 WO2011095668A1 (es) 2010-02-08 2011-02-07 Uso de la yesotoxina, análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y b-amiloide
US13/577,537 US20130035302A1 (en) 2010-02-08 2011-02-07 Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201030162A ES2363975B8 (es) 2010-02-08 2010-02-08 Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide.

Publications (3)

Publication Number Publication Date
ES2363975A1 ES2363975A1 (es) 2011-08-22
ES2363975B2 ES2363975B2 (es) 2012-03-21
ES2363975B8 true ES2363975B8 (es) 2012-10-03

Family

ID=44351443

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201030162A Active ES2363975B8 (es) 2010-02-08 2010-02-08 Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide.

Country Status (4)

Country Link
US (1) US20130035302A1 (es)
EP (1) EP2535335A4 (es)
ES (1) ES2363975B8 (es)
WO (1) WO2011095668A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101741441B1 (ko) 2014-07-24 2017-05-30 삼성중공업 주식회사 자동 도장장치

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053136A2 (en) 2001-12-20 2003-07-03 The Regents Of The University Of California Triple transgenic mouse model of alzheimer's disease
US20110009479A1 (en) * 2007-04-23 2011-01-13 University Of North Carolina At Wilmington Stimulating Neuronal Growth Using Brevetoxins

Also Published As

Publication number Publication date
EP2535335A1 (en) 2012-12-19
US20130035302A1 (en) 2013-02-07
ES2363975A1 (es) 2011-08-22
EP2535335A4 (en) 2013-07-17
WO2011095668A1 (es) 2011-08-11
ES2363975B2 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
EP3466408C0 (en) LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE OF THE POSTERIOR EYE
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112015019412A2 (pt) inibidores de bace1
IN2014MN01982A (es)
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
AR106364A1 (es) Derivados de insulina y sus usos médicos
CL2020000310A1 (es) Análogos de insulina acilados novedosos y usos de estos.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
PH12017500913A1 (en) Substituted bridged urea analogs as sirtuin modulators
EP3500278C0 (en) COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A SELF-COMPLEMENTARY RECOMBINANT ADENO-ASSOCIATED VIRUS
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
BR112014029597A2 (pt) compostos de cromano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2363975

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20120321